What makes #Lyndra’s approach to oral drug delivery unique? Our Chief Medical Officer Richard Scranton, MD, MPH, speaks about how, as part of our core purpose to reinvent medicine for a healthier world, we’re aiming to fundamentally change how pills work. #Adherence

In honor of #WomensHistoryMonth, we’re sharing this quote from our President and Chief Operations Officer @JBallLyndra on her path to success from @ISPEOrg’s Facilities of the Future Conference. Check out quotes from Jess and other panelists: ispe.org/pharmaceutical… #IWD2023

According to @NAMIcommunicate, around 7 million people in the U.S. live with bipolar disorder. World Bipolar Day aims to address stigma through education; we recommend a recent blog from NAMI titled "Understanding Bipolar Disorder": nami.org/Blogs/NAMI-Blo…

Our President & COO Jessica Ballinger is speaking at Harvard Griffin GSAS Biotech Club’s distinguished speaker series today, April 6. She will share her career journey & work since joining Lyndra to finance, build partnerships, manage operations & her advice for the next generation in #STEM

Spring has sprung! We’re celebrating new opportunities as we head into the warmer months in Boston. The season represents rebirth & rejuvenation, carrying an important weight for many cultures. We’re wishing a Happy Easter, Happy Passover & Ramadan Mubarak to those who celebrate

Many Lyndra team members bring a personal passion to their work, including our CEO Patricia Hurter. In recognition of the World Health Organization (WHO)'s #WorldMalariaDay today, read Trish’s personal story of her commitment to malaria eradication & how it inspires her work at Lyndra: linkedin.com/pulse/when-pas…

Today Lyndra announced the dosing of the first participant in our pivotal trial evaluating oral weekly risperidone (LYN-005) in adults with schizophrenia or schizoaffective disorder. Read more here: businesswire.com/news/home/2023… #Lynx #Innovation #Biotech

.Lyndra® Therapeutics began dosing in a clinical trial of risperidone for #schizophrenia and #schizoaffective and #bipolar disorders. The drug would introduce a long-acting oral option to schizophrenia treatment. bit.ly/3Buo4Dd

A new trial testing risperidone (LYN-005) as a weekly oral treatment for patients with #schizophrenia has officially begun. hcplive.com/view/new-trial…

Lyndra has announced leadership changes and an update on pivotal trial progress! Learn more about the announcement in our press release: businesswire.com/news/home/2023…

We’re honored to announce the close of a $101 Million Series E funding round, led by Sarissa Capital and including Sun Pharma and Polaris Partners, to support the development of therapies with our LYNXTM drug delivery platform. businesswire.com/news/home/2023…